In our study, we assessed plasma adiponectin and its correlation with CIMT, as a marker of atherosclerosis, and urine albumin/creatinine ratio (ACR) in patients with NAFLD. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.